<SEC-DOCUMENT>0001415889-24-022989.txt : 20240905
<SEC-HEADER>0001415889-24-022989.hdr.sgml : 20240905
<ACCEPTANCE-DATETIME>20240905195320
ACCESSION NUMBER:		0001415889-24-022989
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20240905
DATE AS OF CHANGE:		20240905

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Athira Pharma, Inc.
		CENTRAL INDEX KEY:			0001620463
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				453368487
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-39503
		FILM NUMBER:		241282673

	BUSINESS ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011
		BUSINESS PHONE:		(425) 620-8501

	MAIL ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M3 Biotechnology, Inc.
		DATE OF NAME CHANGE:	20140924

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Litton Mark James
		CENTRAL INDEX KEY:			0001604834
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		144

	MAIL ADDRESS:	
		STREET 1:		11804 NORTH CREEK PARKWAY SOUTH
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
	<headerData>
        <submissionType>144</submissionType>
                <filerInfo>
            <filer>
                <filerCredentials>
                    <cik>0001604834</cik>
                    <ccc>XXXXXXXX</ccc>
                </filerCredentials>
            </filer>
        <liveTestFlag>LIVE</liveTestFlag>




                </filerInfo>
    </headerData>

     <formData>
        <issuerInfo>
            <issuerCik>0001620463</issuerCik>
			<issuerName>ATHIRA PHARMA, INC.</issuerName>


			    <secFileNumber>001-39503</secFileNumber>


			<issuerAddress>
				<com:street1>18706 NORTH CREEK PARKWAY, SUITE 104</com:street1>
                				<com:city>BOTHELL</com:city>
				<com:stateOrCountry>WA</com:stateOrCountry>
				<com:zipCode>98011</com:zipCode>
			</issuerAddress>

			<issuerContactPhone>(425) 620-8501</issuerContactPhone>
			<nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Mark James Litton</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>

			<relationshipsToIssuer>

				    <relationshipToIssuer>Officer</relationshipToIssuer>
                                				    <relationshipToIssuer>Director</relationshipToIssuer>

			</relationshipsToIssuer>
		</issuerInfo>

				          <securitiesInformation>
			<securitiesClassTitle>Common</securitiesClassTitle>
			<brokerOrMarketmakerDetails>
				<name>Morgan Stanley Smith Barney LLC Executive Financial Services</name>
				<address>
				<com:street1>1 New York Plaza</com:street1>
                				<com:street2>38th Fl.</com:street2>
                				<com:city>New York</com:city>
				<com:stateOrCountry>NY</com:stateOrCountry>
				<com:zipCode>10004</com:zipCode>
				</address>
			</brokerOrMarketmakerDetails>
			<noOfUnitsSold>5032</noOfUnitsSold>
			<aggregateMarketValue>0.56</aggregateMarketValue>
			<noOfUnitsOutstanding>38439375</noOfUnitsOutstanding>
			<approxSaleDate>09/05/2024</approxSaleDate>
			<securitiesExchangeName>NASDAQ</securitiesExchangeName>
		</securitiesInformation>

    		       <securitiesToBeSold>
         <securitiesClassTitle>Common</securitiesClassTitle>
         <acquiredDate>09/03/2024</acquiredDate>
         <natureOfAcquisitionTransaction>Restricted Stock Lapse - See Remarks</natureOfAcquisitionTransaction>
                  <nameOfPersonfromWhomAcquired>Athira Pharma, Inc.</nameOfPersonfromWhomAcquired>
                  <isGiftTransaction>N</isGiftTransaction>
		          <amountOfSecuritiesAcquired>20000</amountOfSecuritiesAcquired>
                  <paymentDate>09/03/2024</paymentDate>
                  <natureOfPayment>Equity Compensation</natureOfPayment>
      </securitiesToBeSold>

    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>


    		<remarks>Shares sold to cover tax obligation from settlement of vested Restricted Stock Units.</remarks>

        <noticeSignature>
            <noticeDate>09/05/2024</noticeDate>
                        <signature> /s/ Mark Worthington, Attorney-in-Fact for Mark Litton</signature>
        </noticeSignature>
	</formData>
    </edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
